A phosphotyrosine switch determines the antitumor activity of ERβ

Bin Yuan, Long Cheng, Huai Chin Chiang, Xiaojie Xu, Yongjian Han, Hang Su, Lingxue Wang, Bo Zhang, Jing Lin, Xiaobing Li, Xiangyang Xie, Tao Wang, Rajeshwar R Tekmal, Tyler J Curiel, Zhi Min Yuan, Richard M Elledge, Yanfen Hu, Qinong Ye, Rong Li

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Estrogen receptors ERα and ERβ share considerable sequence homology yet exert opposite effects on breast cancer cell proliferation. While the proliferative role of ERα in breast tumors is well characterized, it is not clear whether the antitumor activity of ERβ can be mobilized in breast cancer cells. Here, we have shown that phosphorylation of a tyrosine residue (Y36) present in ERβ, but not in ERα, dictates ERβ-specific activation of transcription and is required for ERβ-dependent inhibition of cancer cell growth in culture and in murine xenografts. Additionally, the c-ABL tyrosine kinase and EYA2 phosphatase directly and diametrically controlled the phosphorylation status of Y36 and subsequent ERβ function. A nonphosphorylatable, transcriptionally active ERβ mutant retained antitumor activity but circumvented control by upstream regulators. Phosphorylation of Y36 was required for ERβ-mediated coactivator recruitment to ERβ target promoters. In human breast cancer samples, elevated phosphorylation of Y36 in ERβ correlated with high levels of c-ABL but low EYA2 levels. Furthermore, compared with total ERβ, the presence of phosphorylated Y36-specific ERβ was strongly associated with both disease-free and overall survival in patients with stage II and III disease. Together, these data identify a signaling circuitry that regulates ERβ-specific antitumor activity and has potential as both a prognostic tool and a molecular target for cancer therapy.

Original languageEnglish (US)
Pages (from-to)3378-3390
Number of pages13
JournalJournal of Clinical Investigation
Volume124
Issue number8
DOIs
StatePublished - Aug 1 2014

Fingerprint

Phosphotyrosine
Phosphorylation
Breast Neoplasms
Sequence Homology
Phosphoric Monoester Hydrolases
Heterografts
Estrogen Receptors
Protein-Tyrosine Kinases
Transcriptional Activation
Disease-Free Survival
Tyrosine
Neoplasms
Cell Proliferation
Growth
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A phosphotyrosine switch determines the antitumor activity of ERβ. / Yuan, Bin; Cheng, Long; Chiang, Huai Chin; Xu, Xiaojie; Han, Yongjian; Su, Hang; Wang, Lingxue; Zhang, Bo; Lin, Jing; Li, Xiaobing; Xie, Xiangyang; Wang, Tao; Tekmal, Rajeshwar R; Curiel, Tyler J; Yuan, Zhi Min; Elledge, Richard M; Hu, Yanfen; Ye, Qinong; Li, Rong.

In: Journal of Clinical Investigation, Vol. 124, No. 8, 01.08.2014, p. 3378-3390.

Research output: Contribution to journalArticle

Yuan, B, Cheng, L, Chiang, HC, Xu, X, Han, Y, Su, H, Wang, L, Zhang, B, Lin, J, Li, X, Xie, X, Wang, T, Tekmal, RR, Curiel, TJ, Yuan, ZM, Elledge, RM, Hu, Y, Ye, Q & Li, R 2014, 'A phosphotyrosine switch determines the antitumor activity of ERβ', Journal of Clinical Investigation, vol. 124, no. 8, pp. 3378-3390. https://doi.org/10.1172/JCI74085
Yuan, Bin ; Cheng, Long ; Chiang, Huai Chin ; Xu, Xiaojie ; Han, Yongjian ; Su, Hang ; Wang, Lingxue ; Zhang, Bo ; Lin, Jing ; Li, Xiaobing ; Xie, Xiangyang ; Wang, Tao ; Tekmal, Rajeshwar R ; Curiel, Tyler J ; Yuan, Zhi Min ; Elledge, Richard M ; Hu, Yanfen ; Ye, Qinong ; Li, Rong. / A phosphotyrosine switch determines the antitumor activity of ERβ. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 8. pp. 3378-3390.
@article{154f04aa138e463692db49fd18b64ba4,
title = "A phosphotyrosine switch determines the antitumor activity of ERβ",
abstract = "Estrogen receptors ERα and ERβ share considerable sequence homology yet exert opposite effects on breast cancer cell proliferation. While the proliferative role of ERα in breast tumors is well characterized, it is not clear whether the antitumor activity of ERβ can be mobilized in breast cancer cells. Here, we have shown that phosphorylation of a tyrosine residue (Y36) present in ERβ, but not in ERα, dictates ERβ-specific activation of transcription and is required for ERβ-dependent inhibition of cancer cell growth in culture and in murine xenografts. Additionally, the c-ABL tyrosine kinase and EYA2 phosphatase directly and diametrically controlled the phosphorylation status of Y36 and subsequent ERβ function. A nonphosphorylatable, transcriptionally active ERβ mutant retained antitumor activity but circumvented control by upstream regulators. Phosphorylation of Y36 was required for ERβ-mediated coactivator recruitment to ERβ target promoters. In human breast cancer samples, elevated phosphorylation of Y36 in ERβ correlated with high levels of c-ABL but low EYA2 levels. Furthermore, compared with total ERβ, the presence of phosphorylated Y36-specific ERβ was strongly associated with both disease-free and overall survival in patients with stage II and III disease. Together, these data identify a signaling circuitry that regulates ERβ-specific antitumor activity and has potential as both a prognostic tool and a molecular target for cancer therapy.",
author = "Bin Yuan and Long Cheng and Chiang, {Huai Chin} and Xiaojie Xu and Yongjian Han and Hang Su and Lingxue Wang and Bo Zhang and Jing Lin and Xiaobing Li and Xiangyang Xie and Tao Wang and Tekmal, {Rajeshwar R} and Curiel, {Tyler J} and Yuan, {Zhi Min} and Elledge, {Richard M} and Yanfen Hu and Qinong Ye and Rong Li",
year = "2014",
month = "8",
day = "1",
doi = "10.1172/JCI74085",
language = "English (US)",
volume = "124",
pages = "3378--3390",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

TY - JOUR

T1 - A phosphotyrosine switch determines the antitumor activity of ERβ

AU - Yuan, Bin

AU - Cheng, Long

AU - Chiang, Huai Chin

AU - Xu, Xiaojie

AU - Han, Yongjian

AU - Su, Hang

AU - Wang, Lingxue

AU - Zhang, Bo

AU - Lin, Jing

AU - Li, Xiaobing

AU - Xie, Xiangyang

AU - Wang, Tao

AU - Tekmal, Rajeshwar R

AU - Curiel, Tyler J

AU - Yuan, Zhi Min

AU - Elledge, Richard M

AU - Hu, Yanfen

AU - Ye, Qinong

AU - Li, Rong

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Estrogen receptors ERα and ERβ share considerable sequence homology yet exert opposite effects on breast cancer cell proliferation. While the proliferative role of ERα in breast tumors is well characterized, it is not clear whether the antitumor activity of ERβ can be mobilized in breast cancer cells. Here, we have shown that phosphorylation of a tyrosine residue (Y36) present in ERβ, but not in ERα, dictates ERβ-specific activation of transcription and is required for ERβ-dependent inhibition of cancer cell growth in culture and in murine xenografts. Additionally, the c-ABL tyrosine kinase and EYA2 phosphatase directly and diametrically controlled the phosphorylation status of Y36 and subsequent ERβ function. A nonphosphorylatable, transcriptionally active ERβ mutant retained antitumor activity but circumvented control by upstream regulators. Phosphorylation of Y36 was required for ERβ-mediated coactivator recruitment to ERβ target promoters. In human breast cancer samples, elevated phosphorylation of Y36 in ERβ correlated with high levels of c-ABL but low EYA2 levels. Furthermore, compared with total ERβ, the presence of phosphorylated Y36-specific ERβ was strongly associated with both disease-free and overall survival in patients with stage II and III disease. Together, these data identify a signaling circuitry that regulates ERβ-specific antitumor activity and has potential as both a prognostic tool and a molecular target for cancer therapy.

AB - Estrogen receptors ERα and ERβ share considerable sequence homology yet exert opposite effects on breast cancer cell proliferation. While the proliferative role of ERα in breast tumors is well characterized, it is not clear whether the antitumor activity of ERβ can be mobilized in breast cancer cells. Here, we have shown that phosphorylation of a tyrosine residue (Y36) present in ERβ, but not in ERα, dictates ERβ-specific activation of transcription and is required for ERβ-dependent inhibition of cancer cell growth in culture and in murine xenografts. Additionally, the c-ABL tyrosine kinase and EYA2 phosphatase directly and diametrically controlled the phosphorylation status of Y36 and subsequent ERβ function. A nonphosphorylatable, transcriptionally active ERβ mutant retained antitumor activity but circumvented control by upstream regulators. Phosphorylation of Y36 was required for ERβ-mediated coactivator recruitment to ERβ target promoters. In human breast cancer samples, elevated phosphorylation of Y36 in ERβ correlated with high levels of c-ABL but low EYA2 levels. Furthermore, compared with total ERβ, the presence of phosphorylated Y36-specific ERβ was strongly associated with both disease-free and overall survival in patients with stage II and III disease. Together, these data identify a signaling circuitry that regulates ERβ-specific antitumor activity and has potential as both a prognostic tool and a molecular target for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84905460024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905460024&partnerID=8YFLogxK

U2 - 10.1172/JCI74085

DO - 10.1172/JCI74085

M3 - Article

C2 - 24960160

AN - SCOPUS:84905460024

VL - 124

SP - 3378

EP - 3390

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 8

ER -